Literature DB >> 27456203

Tolerance, loss of tolerance and regaining tolerance to self by immune-mediated events.

Arpad Zsigmond Barabas1, Chad Douglas Cole2, Richard Milton Graeff3, Rene Lafreniere4, Donald Mackay Weir5.   

Abstract

Autoimmunity has both beneficial and harmful aspects. Beneficial aspects include: (1) removal of released intracytoplasmic antigens (ags) (cells at the end of their life span or damaged by outside agents) by specific nonpathogenic IgM autoantibodies and mononuclear cells and (2) recognition and elimination of cancerous cells. In contrast, harmful aspects include: (1) mounting a pathogenic autoimmune response against a tissue-derived ag, a 'modified self,' resulting in autoimmune disease and (2) inability to recognize and eliminate a cancerous clone. The immune system continuously faces internal and external influences; however, even when it is compromised or overwhelmed, it will still endeavor to regain and maintain tolerance to self. To promote this, we developed a 'modified vaccination technique' (MVT) (described as the third vaccination method after active and passive immunizations). It has two components: purified exogenous/endogenous ag (i.e., target ag) and a high-titer-specific antibody (ab) against the target ag made into an immune complex (IC) with predetermined immune-inducing components. The MVT works by ab information transfer (production of same class of immunoglobulin with the same specificity against the target ag that is present in the vaccine), thereby re-establishing tolerance to self (caused by exogenous/endogenous ags) following repeated administration of appropriate ICs. This vaccination technique can be used both prophylactically and therapeutically, and it mimics the immune system's natural abilities to respond to corrective information specifically, rapidly, safely and with minimal side effects and makes this approach a novel solution for many disorders that are difficult or impossible to cure or manage.

Entities:  

Keywords:  Autoantibody; Immune complex; Modified vaccination technique; Tolerance

Mesh:

Substances:

Year:  2017        PMID: 27456203     DOI: 10.1007/s12026-016-8842-6

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  52 in total

1.  Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM.

Authors:  M Boes; T Schmidt; K Linkemann; B C Beaudette; A Marshak-Rothstein; J Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

2.  Elevated antibody response by antigen presentation in immune complexes.

Authors:  Arpad Zsigmond Barabas; Chad Douglas Cole; Zoltan Bernat Kovacs; Rene Lafreniere
Journal:  Med Sci Monit       Date:  2007-05

3.  Formation of immune deposits and disease.

Authors:  G Andres; J R Brentjens; P R Caldwell; G Camussi; S Matsuo
Journal:  Lab Invest       Date:  1986-11       Impact factor: 5.662

4.  Drug-induced lupus. Genetic, clinical, and laboratory features.

Authors:  M C Totoritis; R L Rubin
Journal:  Postgrad Med       Date:  1985-09-01       Impact factor: 3.840

5.  Identification of the enzymatic active site of CD38 by site-directed mutagenesis.

Authors:  C Munshi; R Aarhus; R Graeff; T F Walseth; D Levitt; H C Lee
Journal:  J Biol Chem       Date:  2000-07-14       Impact factor: 5.157

Review 6.  Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review.

Authors:  Annalisa Perna; Arrigo Schieppati; Javier Zamora; Giovanni A Giuliano; Norbert Braun; Giuseppe Remuzzi
Journal:  Am J Kidney Dis       Date:  2004-09       Impact factor: 8.860

Review 7.  Does our current understanding of immune tolerance, autoimmunity, and immunosuppressive mechanisms facilitate the design of efficient cancer vaccines?

Authors:  M Sioud
Journal:  Scand J Immunol       Date:  2009-12       Impact factor: 3.487

Review 8.  B cell targeted therapy in autoimmunity.

Authors:  Miri Blank; Yehuda Shoenfeld
Journal:  J Autoimmun       Date:  2007-03-27       Impact factor: 7.094

Review 9.  Trastuzumab: triumphs and tribulations.

Authors:  R Nahta; F J Esteva
Journal:  Oncogene       Date:  2007-05-28       Impact factor: 9.867

Review 10.  Autoimmunity in 2012.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2013-10       Impact factor: 8.667

View more
  2 in total

1.  Biomarkers and Pathogenic Mechanisms in Autoimmunity.

Authors:  Edward K L Chan; Elias Toubi; Karsten Conrad
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

Review 2.  Antibody-initiated beneficial and harmful immune responses.

Authors:  Arpad Zsigmond Barabas; Chad Douglas Cole; Rene Lafreniere
Journal:  Immunol Res       Date:  2018-12       Impact factor: 2.829

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.